February 27, 2007HypertensionOpen Access

Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure

View Full Paper

Ask AI

Bookmark

Why the study?

Does intravenous BAY 58-2667 improve hemodynamics and renal function in a model of tachypacing-induced severe congestive heart failure?

Population

Model of tachypacing-induced severe congestive heart failure

Design

Preclinical

Authors

GBGuido BoerrigterZentralklinik Bad Berka LCLisa C. Costello‐BoerrigterZentralklinik Bad Berka ACAlessandro CataliottiHeart Failure & Transplant

Discussion

Member takes

Implication

Hypothesis-generating for BAY 58-2667 in experimental HF; human trials required before clinical consideration.

Structured PICO

Does intravenous BAY 58-2667 improve hemodynamics and renal function in a model of tachypacing-induced severe congestive heart failure?

Population

Model of tachypacing-induced severe congestive heart failure

Intervention

Intravenous administration of BAY 58-2667 (0.1 and 0.3 microg/kg per minute)

Outcome

Cardiorenal actions including hemodynamics (mean arterial, right atrial, pulmonary artery, and pulmonary capillary wedge pressure), cardiac output, and renal blood flowsurrogate

In an experimental model of severe heart failure, the soluble guanylate cyclase activator BAY 58-2667 improved cardiac hemodynamics and renal blood flow without neurohumoral activation.

Cite This Study

Boerrigter et al. (2007) studied this question.

synapsesocial.com/papers/6a0270147adabae4d9372d42 https://doi.org/10.1161/hypertensionaha.106.083832

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider